STOCK TITAN

Trevi Therapeutics Inc - TRVI STOCK NEWS

Welcome to our dedicated news page for Trevi Therapeutics (Ticker: TRVI), a resource for investors and traders seeking the latest updates and insights on Trevi Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Trevi Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Trevi Therapeutics's position in the market.

Rhea-AI Summary
Trevi Therapeutics announces data presentation on the reduction of cough bouts with nalbuphine ER in patients with IPF in the Phase 2 CANAL trial at the ATS 2024 International Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.13%
Tags
none
-
Rhea-AI Summary
Trevi Therapeutics, Inc. (TRVI) will participate in key events in April 2024, including the 23rd Annual Needham Virtual Healthcare Conference and the European Pulmonary Fibrosis Foundation Patient Summit. The company will discuss the investigational therapy Haduvio™ for chronic cough in idiopathic pulmonary fibrosis and refractory chronic cough.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
conferences
-
Rhea-AI Summary
Trevi Therapeutics appoints Margaret Garin, MD, MSCR, as Vice President of Clinical Development to advance Haduvio for chronic cough treatment. Dr. Garin brings over 14 years of industry and academic research experience, leading Phase 2b study and Phase 3 RCC program at Bellus Health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.87%
Tags
management clinical trial
Rhea-AI Summary
Trevi Therapeutics, Inc. (TRVI) announces financial results for Q4 2023, reiterates guidance for Phase 2a RIVER trial of Haduvio in RCC and Phase 2b CORAL trial for chronic cough in IPF. The company expects important data readouts in the second half of 2024, with enrollment progressing in ongoing trials. Trevi ended 2023 with $83.0 million in cash and cash equivalents, ensuring cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.52%
Tags
-
Rhea-AI Summary
Trevi Therapeutics, Inc. (Nasdaq: TRVI) will host a conference call and webcast to discuss the investigational therapy Haduvio™ for chronic cough in IPF and RCC. The event will cover financial results for Q4 2023 and the full year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.39%
Tags
conferences earnings
-
Rhea-AI Summary
Trevi Therapeutics, Inc. (TRVI) announces senior management's participation in upcoming healthcare conferences in March 2024 to discuss the investigational therapy Haduvio™ for chronic cough in IPF and RCC. Events include TD Cowen 44th Annual Health Care Conference, Connecticut Rare Disease Forum, Leerink Partners Global Biopharma Conference, and BIO-Europe Spring.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.78%
Tags
conferences
Rhea-AI Summary
Trevi Therapeutics, Inc. (Nasdaq: TRVI) will be presenting at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 14, 2024, to discuss the development of the investigational therapy Haduvio™ for patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). President and CEO Jennifer Good, along with CFO Lisa Delfini, will participate in investor meetings during the virtual event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.29%
Tags
conferences
-
Rhea-AI Summary
Trevi Therapeutics, Inc. (TRVI) provides a preview of business updates and announces attendance at the 13th Annual LifeSci Partners Corporate Access Event. The company is developing the investigational therapy Haduvio™ for patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.34%
Tags
none
-
Rhea-AI Summary
Trevi Therapeutics, Inc. (Nasdaq: TRVI) initiates Phase 2b CORAL clinical trial for Haduvio in IPF chronic cough patients after positive results from Phase 2a CANAL trial showing a 75.1% reduction in daytime cough frequency. The trial will evaluate three doses of Haduvio against placebo in approximately 160 IPF patients with chronic cough, with primary efficacy endpoint being the relative change in 24-hour cough frequency at the end of Week 6 versus baseline for Haduvio compared to placebo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
Rhea-AI Summary
TRVI: Trevi Therapeutics Initiates Phase 2a RIVER Trial of Haduvio in Refractory Chronic Cough Patients, Expects Topline Data in Second Half of 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
Trevi Therapeutics Inc

Nasdaq:TRVI

TRVI Rankings

TRVI Stock Data

201.36M
39.23M
1.28%
80.72%
1.51%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
New Haven

About TRVI

trevi therapeutics, inc. is a late-stage biopharmaceutical company focused on developing nalbuphine® er for chronic pruritic conditions. pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions. the company is pursuing several pruritic conditions for clinical development, including its lead indication of prurigo nodularis. prurigo nodularis is a chronic pruritic dermatologic condition characterized by the presence of pruriginous lesions (excoriative/ulcerative papules and nodules) on the skin. there are no approved therapies in the us or eu for this condition. nalbuphine® er is an oral extended release synthetic opioid with a dual mechanism of action, mu receptor antagonist and kappa receptor agonist, both of which have been shown in research to be effective in abolishing itch. because of nalbuphine® er’s unique dual mechanism of action, which has shown efficacy in addressing pruritus in human clinical trials, the company believes nalbuphine® er can